For years, the longevity conversation was dominated by one question: how can we live longer? Today, that question is evolving into something far more relevant: how can we live healthier for longer? As healthcare systems worldwide grapple with ageing populations and the growing burden of chronic disease, prevention is becoming a central priority rather than a niche concept. Nutrition, once viewed primarily as lifestyle advice, is increasingly supported by rigorous clinical research and emerging as an essential component of evidence-based healthcare. At the intersection of this shift sits L-Nutra, one of the leading companies advancing the concept of “Food as Medicine” through clinically validated nutritional interventions.
To explore how longevity is evolving from a scientific concept into a practical healthcare strategy, Longevity Italia sat down with Andrea Ghirardi to discuss the future of preventive nutrition, the challenges of scaling innovation, and why trust will ultimately define the next chapter of the longevity industry.
Andrea Ghirardi, CEO EMEA and President of L-Nutra, has spent more than 15 years building and scaling science-driven businesses across Europe and the United States. Recognized among Forbes Italy‘s Top 100 CEOs, he has become a leading voice on the convergence of longevity science, nutrition, artificial intelligence and personalized medicine. Under his leadership, L-Nutra is expanding its presence across Europe while translating cutting-edge research into practical solutions for clinicians, healthcare systems and consumers.
L-Nutra has become one of the most recognized companies in the “Food as Medicine” and longevity nutrition space. What do you see as L-Nutra’s most important contribution to the longevity field?
One thing I’ve noticed over the last few years is that the conversation around longevity has become much more mature. It used to be centred on living longer. Today, people are asking a different question: how do we stay healthier for longer? That’s a much more meaningful conversation. I believe L-Nutra has helped accelerate that shift by bringing nutritional science into mainstream healthcare discussions, not as an alternative to medicine, but as part of a broader preventive approach. That’s probably the contribution I’m most proud of. We’ve helped show that nutrition, when supported by robust clinical research, deserves a place in evidence-based healthcare.
Healthcare doesn’t change when science changes. It changes when science becomes practical.
As CEO EMEA and President of L-Nutra, your role sits at the intersection of science, innovation and commercialization. What has been the most challenging aspect of translating cutting-edge longevity research into scalable products and programs?
If there’s one lesson this industry keeps teaching me, it’s that good science is only the starting point. The real challenge is earning trust. Every day you’re speaking to clinicians, healthcare systems, regulators, employers and consumers. Each looks at innovation through a different lens, and each has a different threshold for adoption. My role is often less about commercialising innovation and more about helping those worlds understand each other. That’s where scale begins: not when the science is published, but when people trust it enough to use it.
You have previously spoken about the need to democratize longevity. What barriers still prevent longevity interventions from becoming mainstream?
If you’d asked me this question five years ago, I would probably have said awareness. Today I’d give a different answer. People understand that prevention matters. They’re actively looking for ways to take a more proactive role in their health. The challenge has shifted toward credibility.
As an industry, we need to spend less time making longevity sound exciting and more time generating evidence, communicating responsibly and focusing on outcomes. The second challenge is accessibility. Prevention becomes mainstream when it naturally fits into healthcare and into everyday life.
Which trends do you believe will have the greatest impact on healthspan over the next decade, and which are currently overhyped?
I try not to get too excited about individual technologies. Every few years our industry falls in love with a new buzzword. What interests me much more is convergence. AI, biomarkers and precision nutrition become genuinely valuable when they work together. That’s when prevention becomes more personalised, more measurable and more relevant to clinical practice. If I have one note of caution, it’s this: ageing is incredibly complex. Whenever someone suggests there’s going to be one intervention that changes everything, I’m naturally sceptical. Healthcare rarely evolves that way.
Looking at the broader longevity ecosystem, from startups and investors to healthcare systems and regulators, what gives you the most optimism today, and what concerns you the most?
What gives me confidence is that longevity is no longer a conversation happening only inside research centres. I now find myself discussing the same themes with employers, insurers, policymakers and investors. When very different sectors start asking the same questions, it’s usually a sign that something fundamental is changing. At the same time, maturity brings responsibility.
Commercial interest is accelerating, consumer demand is growing and investment continues to increase. That’s positive, but it also means the industry has to be disciplined. Trust is remarkably difficult to earn in healthcare, and surprisingly easy to lose.
The organisations that will shape this sector over the next decade won’t necessarily be the loudest ones. They’ll be the ones that quietly build credibility over time.
